Saturday 17 October 2026
Export CPHI’s income statement to Excel — free account
China Pharma Holdings, Inc.
CPHI Healthcare Drug Manufacturers Specialty & Generic
China Pharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, down 8.49% from fiscal 2024. In the quarter to June 2026, revenue fell 7.56%, EPS grew 75.0%, free cash flow fell 113.6% and total debt fell 2.92%, each against the same quarter a year earlier.
0.71
0.02
−2.74%
Follow CPHI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.83 | 3.91 | 1.25 | 1.86 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(815.38) | (282.41) | 34.16 | (36.98) | |
P/B ratio |
0.74 | 0.42 | 0.23 | 0.91 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.59 | 4.68 | 1.97 | 2.60 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(211.66) | 112.16 | 54.92 | 35.71 | |
EV/FCF |
(89.29) | (727.53) | (184.67) | (64.05) | |
Quick Ratio |
0.07 | 0.06 | 0.09 | 0.09 | |
Current Ratio |
0.26 | 0.28 | 0.32 | 0.35 | |
Net Debt/EBITDA |
(5.72) | (12.88) | (2.60) | (6.11) | |
Debt/Assets |
4.38% | 4.27% | 6.38% | 12.38% | |
Debt/Equity |
0.05 | 0.05 | 0.09 | 0.24 | |
Asset Turnover |
0.13 | 0.13 | 0.18 | 0.28 | |
Operating CF/Net income |
0.02 | 0.05 | (0.12) | 0.31 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.21) | |
Interest Coverage |
(54.23) | (42.97) | (53.11) | (26.17) | |
Research and Development Expense of Revenue |
2.01% | 8.52% | 15.50% | 5.33% | |
Selling, General and Administrative Expense of Revenue |
157.20% | 134.41% | 96.90% | 66.50% | |
Intangible Assets out of Total Assets |
0.86 | 0.86 | 0.78 | 0.56 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.24) | (0.39) | (1.14) | (0.68) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(65.15%) | (90.16%) | (61.98%) | (54.87%) | |
Free Cash Flow Yield |
(1.24%) | (0.16%) | (0.85%) | (2.18%) | |
Revenue per Share |
0.02 | 0.04 | 0.29 | 0.20 | |
Operating CF per Share |
0.00 | 0.00 | 0.04 | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.03 | (0.07) | |
Cash per Share |
0.01 | 0.01 | 0.08 | 0.08 | |
Shareholders Equity per Share |
0.89 | 1.45 | 5.30 | 2.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.89 | 1.45 | 5.30 | 2.15 | |
Free Cash Flow |
(0.03) | (0.06) | 0.15 | (0.28) | |
Working Capital |
(5.67) | (5.26) | (5.05) | (4.29) | |
Capital Expenditures |
— | — | (0.01) | (0.07) | |
Net Current Asset Value |
(6.52) | (6.12) | (5.91) | (5.16) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.10 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.28 | 0.31 | 0.28 | 0.33 | |
Average Payables |
0.63 | 0.69 | 0.56 | 0.49 | |
Average Inventory |
1.52 | 1.74 | 1.94 | 2.07 | |
Average Assets |
29.24 | 29.68 | 22.94 | 14.64 | |
Average Common Equity |
21.32 | 22.00 | 15.24 | 7.42 |
Columns are period end dates